retapamulin - search results

United States - English - NLM (National Library of Medicine)

altabax- retapamulin ointment

almirall, llc - retapamulin (unii: 4mg6o8991r) (retapamulin - unii:4mg6o8991r) - retapamulin 10 mg - altabax® is indicated for use in adults and pediatric patients aged 9 months and older for the topical treatment of impetigo (up to 100 cm2 in total area in adults or 2% total body surface area in pediatric patients aged 9 months or older) due to staphylococcus aureus (methicillin-susceptible isolates only) or streptococcus pyogenes [see clinical studies (14)] . safety in patients younger than 9 months has not been established. to reduce the development of drug-resistant bacteria and maintain the effectiveness of altabax and other antibacterial drugs, altabax should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. none. risk summary there are no available data on altabax use in pregnant women to inform any drug associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes. retapamulin is negligibly absorbed systemically following topical administration and maternal use is not expected to result in fetal exp

United States - English - NLM (National Library of Medicine)

altabax- retapamulin ointment

physicians total care, inc. - retapamulin (unii: 4mg6o8991r) (retapamulin - unii:4mg6o8991r) - retapamulin 10 mg in 1 g - altabax is indicated for use in adults and pediatric patients aged 9 months and older for the topical treatment of impetigo (up to 100 cm2 in total area in adults or 2% total body surface area in pediatric patients aged 9 months or older) due to staphylococcus aureus (methicillin-susceptible isolates only) or streptococcus pyogenes [see clinical studies (14)] . to reduce the development of drug-resistant bacteria and maintain the effectiveness of altabax and other antibacterial drugs, altabax should none. pregnancy category b . effects on embryo-fetal development were assessed in pregnant rats given 50, 150, or 450 mg/kg/day by oral gavage on days 6 to 17 postcoitus. maternal toxicity (decreased body weight gain and food consumption) and developmental toxicity (decreased fetal body weight and delayed skeletal ossification) were evident at doses ≥150 mg/kg/day. there were no treatment-related malformations observed in fetal rats. retapamulin was given as a continuous intravenous infusion to pregnan

United States - English - NLM (National Library of Medicine)

altabax- retapamulin ointment

rebel distributors corp. - retapamulin (unii: 4mg6o8991r) (retapamulin - unii:4mg6o8991r) - retapamulin 10 mg in 1 g - altabax is indicated for use in adults and pediatric patients aged 9 months and older for the topical treatment of impetigo (up to 100 cm2 in total area in adults or 2% total body surface area in pediatric patients aged 9 months or older) due to staphylococcus aureus (methicillin-susceptible isolates only) or streptococcus pyogenes [see clinical studies (14)] . to reduce the development of drug-resistant bacteria and maintain the effectiveness of altabax and other antibacterial drugs, altabax should none. 8.1 pregnancy pregnancy category b . effects on embryo-fetal development were assessed in pregnant rats given 50, 150, or 450 mg/kg/day by oral gavage on days 6 to 17 postcoitus. maternal toxicity (decreased body weight gain and food consumption) and developmental toxicity (decreased fetal body weight and delayed skeletal ossification) were evident at doses ≥150 mg/kg/day. there were no treatment-related malformations observed in fetal rats. retapamulin was given as a continuous intravenous infusion to pre

Australia - English - Department of Health (Therapeutic Goods Administration)

altargo retapamulin 1% w/w ointment tube

glaxosmithkline australia pty ltd - retapamulin -

European Union - English - EMA (European Medicines Agency)

altargo

glaxo group ltd - retapamulin - impetigo; staphylococcal skin infections - antibiotics and chemotherapeutics for dermatological use - short term treatment of the following superficial skin infections: , impetigo;, infected small lacerations, abrasions or sutured wounds. , see sections 4.4 and 5.1 for important information regarding the clinical activity of retapamulin against different types of staphylococcus aureus. consideration should be given to official guidance on the appropriate use of antibacterial agents.,